Shopping Cart 0
Cart Subtotal
USD 0

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline Review, H2 2017, provides an overview of the Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline landscape.

HIV is a virus which attacks the immune system, and weakens ability to fight infections and disease. Symptoms include fever, sore throat, body rash, joint pain, muscle pain and swollen glands. The most common ways HIV is spread are by having vaginal or anal intercourse without a condom with someone who has HIV/AIDS, sharing needles or syringes with someone who has HIV/AIDS, being deeply punctured with a needle or surgical instrument contaminated with HIV and getting HIV-infected blood, semen, or vaginal secretions into open wounds or sores.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Human Immunodeficiency Virus (HIV) Infections (AIDS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 1, 15, 46, 42, 1, 4, 104, 66 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 16, 20, 55 and 62 molecules, respectively.

Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

Introduction

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Overview

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Therapeutics Development

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Therapeutics Assessment

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Companies Involved in Therapeutics Development

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Drug Profiles

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Dormant Projects

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Discontinued Products

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Product Development Milestones

Appendix


List Of Figure

List of Figures

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Products under Development by Companies, H2 2017 (Contd..7), H2 2017

Products under Development by Companies, H2 2017 (Contd..8), H2 2017

Products under Development by Companies, H2 2017 (Contd..9), H2 2017

Products under Development by Companies, H2 2017 (Contd..10), H2 2017

Products under Development by Companies, H2 2017 (Contd..11), H2 2017

Products under Development by Companies, H2 2017 (Contd..12), H2 2017

Products under Development by Companies, H2 2017 (Contd..13), H2 2017

Products under Development by Companies, H2 2017 (Contd..14), H2 2017

Products under Development by Universities/Institutes, H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..5), H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..6), H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..7), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Number of Products by Stage and Molecule Type, H2 2017 (Contd..1), H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by AbbVie Inc, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by Abivax SA, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by AdAlta Ltd, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by Advanced Genetic Systems Inc, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by Akshaya Bio Inc, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by Altor BioScience Corp, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by Altravax Inc, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by Amarna Therapeutics BV, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by American Gene Technologies International Inc, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by Amunix Operating Inc, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by Antigen Express Inc, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by Aphios Corp, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by Apotex Inc, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by Argos Therapeutics Inc, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by B Cell Design SAS, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by Biological Mimetics Inc, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by Bionor Pharma AS, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by Biotron Ltd, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by Bolder Biotechnology Inc, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by Bristol-Myers Squibb Co, H2 2017

Human Immunodeficiency Virus (HIV) Infections (AIDS)-Pipeline by Bukwang Pharm Co Ltd, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

AbbVie Inc

Abivax SA

AdAlta Ltd

Advanced Genetic Systems Inc

Akshaya Bio Inc

Altor BioScience Corp

Altravax Inc

Amarna Therapeutics BV

American Gene Technologies International Inc

Amunix Operating Inc

Antigen Express Inc

Aphios Corp

Apotex Inc

Argos Therapeutics Inc

B Cell Design SAS

Biological Mimetics Inc

Bionor Pharma AS

Biotron Ltd

Bolder Biotechnology Inc

Bristol-Myers Squibb Co

Bukwang Pharm Co Ltd

Cadila Healthcare Ltd

Calimmune Inc

CEL-SCI Corp

Celgene Corp

Celldex Therapeutics Inc

Chipscreen Biosciences Ltd

Cocrystal Pharma Inc

CompleGen Inc

Consegna Pharma Inc

ContraVir Pharmaceuticals Inc

Critical Outcome Technologies Inc

Curevac AG

Cytodyn Inc

Enzo Biochem Inc

eTheRNA Immunotherapies NV

Etubics Corp

Excision BioTherapeutics Inc

FIT Biotech Oy

Fountain Biopharma Inc

Frontier Biotechnologies Inc

Galmed Pharmaceuticals Ltd

GeneCure LLC

Genetic Immunity Inc

GeoVax Labs Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Globeimmune Inc

GW Pharmaceuticals Plc

Hanmi Pharmaceuticals Co Ltd

Heat Biologics Inc

iCo Therapeutics Inc.

ID Pharma Co Ltd

IGXBio Inc

Immune Response BioPharma Inc

ImmunoClin Corp

Immunocore Ltd

Immunotope Inc

Immusoft Corp

ImQuest Life Sciences Inc

InnaVirVax SA

Innovative Targeting Solutions Inc

Inovio Pharmaceuticals Inc

Japan Tobacco Inc

Johnson & Johnson

Kainos Medicine Inc

Karyopharm Therapeutics Inc

KPI Therapeutics Inc

Kymab Ltd

Longevity Biotech Inc

MacroGenics Inc

Medivir AB

Merck & Co Inc

Moderna Therapeutics Inc

Mologen AG

Mycenax Biotech Inc

Mymetics Corp

Myrexis Inc

NanoViricides Inc

Navigen Inc

NeED Pharma srl

New World Laboratories Inc

Novartis AG

Omeros Corp

Oncolys BioPharma Inc

Oncovir Inc

Orbis Biosciences Inc

Osel Inc

OyaGen Inc

PaxVax Inc

Peregrine Pharmaceuticals Inc

Pharis Biotec GmbH

Phoenix Biotechnology Inc

PlantForm Corp

Profectus BioSciences Inc

Recombio SL

Relmada Therapeutics Inc

Rodos BioTarget GmbH

Samjin Pharm Co Ltd

Sangamo Therapeutics Inc

Sanofi

Sanofi Pasteur SA

Spider Biotech

Spring Bank Pharmaceuticals Inc

ST Pharm Co., Ltd.

Starpharma Holdings Ltd

Susavion Biosciences Inc

Taiga Biotechnologies Inc

TaiMed Biologics Inc

Takara Bio Inc

Takeda Pharmaceutical Co Ltd

TechnoVax Inc

TeneoBio Inc

Theratechnologies Inc

Theravectys SA

Transgene Biotek Ltd

TVAX Biomedical Inc

United Biomedical Inc

Vaccibody AS

Vault Pharma Inc

VG Life Sciences Inc

Vichem Chemie Research Ltd

ViiV Healthcare UK Ltd

Viriom Inc

ViroStatics srl

XL-protein GmbH